What Ferrum Lek Treats: Main Uses and Benefits

Ferrum Lek is commonly used for the management of significant iron deficiency in situations where standard oral iron treatment may not be appropriate or has failed. Such intravenous iron preparations may be considered relevant when oral supplements cannot be given or have not worked effectively. This preparation is applied across domains where additional symptomatic support is needed to restore iron levels in cases such as refractory iron deficiency, conditions where absorption is affected (e.g., IBD, post-gastric surgery), and high-demand scenarios like late-stage pregnancy or significant blood loss.

The medication is commonly used to help with symptom clusters that interfere with daily functioning, addressing symptoms related to systemic imbalance (chronic fatigue, weakness) and symptoms of increased neurological activity (headaches, irritability). This approach contributes to improved comfort during symptomatic periods.

Quick Fact: Therapeutic Use
Applied in clinical settings that involve acute or unstable symptom patterns where oral iron has failed or absorption is compromised.

Who Can and Cannot Use Ferrum Lek?

The eligibility to use Ferrum Lek (Iron(III) hydroxide complex) is strictly governed by regulatory documentation, based on the patient's existing health conditions and age.

Eligibility Scope

Category	Regulatory Statement
Populations Contraindicated	Patients with known hypersensitivity to the components or with conditions leading to iron overload (e.g., hemochromatosis, hemosiderosis) are prohibited from use. The medicine is also contraindicated in anemias not caused by iron deficiency and in disorders of iron utilization (e.g., thalassemia).
Age and Reproductive Status	The injectable solution is contraindicated during the first trimester of pregnancy. It is not recommended for infants under 4 months and is generally not intended for children under 12 years (oral forms). Use during the second and third trimesters is permitted only if medically essential.
Conditional Use (Requires Caution)	Use requires close medical supervision for patients with hepatic impairment, renal impairment, pre-existing cardiovascular disease, or chronic conditions like severe asthma or rheumatoid arthritis due to increased risk of complications or allergic reactions.

The interaction profile for Ferrum Lek (Dextriferron), an injectable iron complex, is defined by specific safety risks with co-administered medicines and documented interference with laboratory testing procedures, based on official regulatory documents.

Drug and Substance Interactions

Co-administration with Angiotensin-Converting Enzyme (ACE) Inhibitor drugs is associated with a regulatory warning. Official prescribing information documents that using medicines from the ACE Inhibitor class concurrently may increase the potential risk for a severe anaphylactic-type reaction. This is classified as a pharmacodynamic risk augmentation.

The medicine carries a formal restriction against concurrent iron preparations. The administration of any additional oral or parenteral iron products is restricted to prevent the accumulation of excess iron, a condition formally known as iatrogenic hemosiderosis. Consequently, the medicine must not be administered to individuals who already have evidence of iron overload.

Interaction with Diagnostic Tests

The presence of the Dextriferron complex in the system constitutes a formally documented interaction with the testing procedure itself.

• Serum Iron Determinations: Assays, particularly colorimetric methods, may yield non-meaningful values for approximately three weeks following the injection.
• Other Blood Analytes: The product is known to cause falsely elevated values for serum bilirubin and falsely decreased values for serum calcium.
• Bone Scans: Interference is documented for diagnostic bone scans utilizing technetium-labeled bone-seeking agents, which can show altered uptake and accumulation patterns.

How Ferrum Lek Works

Ferrum Lek is an Iron(III)-hydroxide Polymaltose Complex (IPC). Its structure chemically resembles ferritin, the natural physiological iron-storage protein. This structural similarity facilitates its selective transport across the mucosal cells of the small intestine via an active, saturable mechanism, specifically involving receptor-mediated endocytosis, rather than relying on the passive diffusion typical of simple iron salts.

Once internalized by the mucosal cell, the ferric iron ( Fe^3+) is released from the IPC structure. The Fe^3+ state exhibits low reactivity, a property that minimizes the production of damaging reactive oxygen species and subsequent oxidative stress within the gastrointestinal lumen. The released iron subsequently enters the systemic circulation through controlled binding to transferrin, the primary iron transport protein. This complex is then delivered to the bone marrow and other tissues, supporting iron-dependent biological processes and facilitating the replenishment of physiological iron stores.

Administration of Ferrum Lek

Ferrum Lek is available in several formulations, including chewable tablets and syrup for oral use, as well as solutions for parenteral administration. The choice of formulation and the specific method of use depend on the clinical indication and the patient's individual requirements.

Oral Formulations

Oral forms of Ferrum Lek, such as chewable tablets and syrup, are designed for ease of administration. The tablets may be chewed or swallowed whole. The syrup can be taken directly or mixed with fruit or vegetable juices to suit patient preference. These oral forms are typically taken during or immediately after a meal to support integration into the daily routine.

Parenteral Administration

The injectable form of Ferrum Lek is intended for clinical situations where oral supplementation is not appropriate or effective. This formulation is administered by healthcare professionals through deep intramuscular injection or intravenous infusion. The procedure is performed in a controlled environment to ensure proper technique and monitoring.

General Considerations

The duration of use is determined by the specific needs of the individual and the underlying reason for supplementation. Consistent application as directed by a healthcare provider is a standard aspect of managing iron levels. It is important to follow the specific guidance provided for each formulation to ensure the intended application is maintained throughout the course of use.

Research has explored the role of injectable iron dextran complex in Iron Deficiency Anemia (IDA) through several clinical studies. Researchers utilized Randomized Controlled Trials (RCTs) and controlled interventional studies, often including oral iron supplements or other intravenous products as comparators. These studies typically focused on adult patients with IDA who had either experienced difficulty tolerating oral iron or had an inadequate response to it.

The research examined key hematologic outcomes, monitoring the change in Hemoglobin (Hb) concentration and the evaluation of body iron stores using biomarkers like serum ferritin. Findings describe patterns observed in these studies where administration of the injectable complex was monitored for measured changes in key iron markers, consistent with iron repletion.

Evidence has also been studied for patients with chronic underlying diseases. Research has explored the role of intravenous iron in patient cohorts with chronic kidney disease (CKD) and chronic heart failure. Studies in these specific groups often focused on outcomes related to functional status and patient-reported symptoms rather than only hematologic parameters. Findings describe patterns observed in which the administration of intravenous iron to patients was observed for changes in these functional metrics, though this evidence often relies on the broader class of intravenous iron compounds.

Specific research has also been observed in special populations, such as pregnant women with IDA, where research monitored maternal iron status and hematologic parameters over defined time intervals. Follow-up durations in most key trials were limited to the short- and medium-term, typically observing responses over several weeks to a few months.

What is still uncertain about research for Ferrum Lek includes a recognized lack of comparative evidence against newer parenteral iron alternatives. Additionally, the historical context of the older, high-molecular-weight iron dextran (HMWID) remains a noted limitation in the literature, though the current formulation is discussed in research literature in the context of this older product.

Key Studies & References Iron deficiency anaemia: assessment and management (NICE Guideline NG150)

Common questions about Ferrum Lek (FAQ)

---

Q: What is the primary medical purpose of Ferrum Lek?

According to official product information, the medicine is used for two main purposes: to treat latent iron deficiency and to address iron deficiency anemia, which is also called overt iron deficiency. The medicine is also indicated for the prevention of iron deficiency, particularly during pregnancy.

Q: Is Ferrum Lek used to treat all types of iron deficiency, or only certain kinds?

Regulatory warnings specify that this medicine is intended only for iron deficiency-related conditions. It should not be used if a patient has anemia caused by other factors, such as hemolytic anemia or a vitamin B deficiency. This distinction is based on the condition the medicine is intended to address.

Q: Are there known interactions between Ferrum Lek and common anti-inflammatory drugs?

Official regulatory documents for the oral form of Ferrum Lek state that, so far, no specific interactions with other medicines, including anti-inflammatory drugs, have been described. Official guidance generally recommends informing a healthcare provider about all medicines being used.

Q: Is Ferrum Lek suitable for use in children, and if so, at what ages is the syrup typically recommended?

The syrup formulation is typically indicated for children between the ages of 1 and 12 years. Official product information notes that the syrup is generally not recommended for infants under 1 year of age, as the necessary dose for that group is too small to measure accurately.

Q: What is the role of Ferrum Lek in treating latent iron deficiency?

Official documents confirm that treating latent iron deficiency is one of the medicine’s primary indications. Latent iron deficiency refers to a lack of iron stores in the body before overt anemia fully develops. Specific dosing guidelines are provided in the product information for addressing this condition.

Q: Can taking Ferrum Lek lead to iron overload in the body?

Official warnings advise special caution regarding overdose, particularly in young children, due to the inherent risks of iron products. However, regulatory reports indicate that no cases of poisoning or excessive iron overload caused by the chewable tablets have been reported so far. The medicine is administered based on calculations to correct the patient's individual iron deficit.

Q: Does Ferrum Lek interact with commonly used over-the-counter pain relievers?

According to regulatory information for the oral form, no specific interactions between this medicine and other drugs, including commonly used over-the-counter pain relievers, have been described so far. It is generally recommended to provide a healthcare provider with a full list of medicines being used.

Q: Is Ferrum Lek known to interact with thyroid medications?

Official regulatory documents for the oral form of Ferrum Lek state that no specific interactions with other medicines, including thyroid medications, have been described so far.

Q: Are there any known interactions between Ferrum Lek and widely used contraceptive pills?

Official product information for the oral formulation indicates that no specific interactions between the product and other medicines, including contraceptive pills, have been described so far.

Q: What is serum ferritin, and why is it important when measuring Ferrum Lek treatment?

Serum ferritin is a measurement of the body’s primary iron storage protein. Because the goal of treatment is to replenish these iron stores, regulatory information notes that treatment duration is often guided by blood test results, which may include measuring ferritin levels.

Q: Is black or dark stool a common and expected effect of taking Ferrum Lek?

Yes, official product information confirms that it is possible for the stool to become dark or black while taking Ferrum Lek, as is the case with other iron preparations. This change is noted as a symptom that is not clinically significant.

Q: Can Ferrum Lek cause stomach discomfort or nausea?

Regulatory documents list a range of possible digestive side effects. These reported effects include general stomach discomfort, pain, and feelings of nausea or vomiting.

Q: What are the most commonly reported gastrointestinal side effects associated with Ferrum Lek?

The most commonly reported gastrointestinal side effects in regulatory documents include digestive issues such as stomach pain and discomfort. Other reported effects are constipation, diarrhea, nausea, and vomiting.

Q: Are there any common foods or drinks that are known to interfere with the absorption of Ferrum Lek?

Regulatory instructions specify that the medicine should be taken during or immediately after a meal. The syrup formulation is unique in that it is also officially indicated to be mixed with fruit or vegetable juice or added to food.

Q: What are the official recommendations regarding the use of Ferrum Lek during pregnancy?

Official regulatory documents confirm that the medicine is indicated for use during pregnancy. It is used both to prevent iron deficiency from occurring and to treat iron deficiency anemia in pregnant women, with specific dosing regimens provided for these purposes.

Q: What information is available about using Ferrum Lek while breastfeeding?

Official dosing guidelines confirm that the medicine is indicated for use while breastfeeding. The product information provides specific dosing recommendations for breastfeeding women, generally placing them in the same category as other adults for treatment.

Q: Are there different usage conditions for the Ferrum Lek syrup versus the chewable tablets?

Yes, the official patient leaflets describe different ways to take each form. The chewable tablets can be chewed or swallowed whole, whereas the syrup can be mixed with fruit or vegetable juice or added directly to food.

Q: What underlying medical conditions might prevent a person from being eligible to use Ferrum Lek?

According to regulatory documents, the medicine is contraindicated for patients with certain conditions. These include anemia not caused by iron deficiency (such as hemolytic anemia) and those who have a known hereditary fructose intolerance.

Q: Is Ferrum Lek considered a prescription-only medicine?

Official information regarding availability indicates that the chewable tablets may be available without a prescription in some regions. This classification, however, can vary depending on the local health authority where the product is sold.

Q: Can the syrup formulation of Ferrum Lek cause discoloration of the teeth?

Official product information states that tooth discoloration is possible during treatment with the syrup formulation. This discoloration is typically described as temporary. It may resolve after treatment is stopped or can be addressed by professional dental cleaning procedures.

Q: What is the definition of a hypersensitivity reaction related to iron preparations like Ferrum Lek?

The product information contraindicates its use if a person has a known allergy or hypersensitivity to the product itself or any of its inactive ingredients. A hypersensitivity reaction indicates an overreaction by the body’s immune system to the substance.

Q: What information is available on Ferrum Lek use for adolescent patients?

Official dosing guidelines for the chewable tablets generally categorize adolescents, specifically children over 12 years of age, within the adult dose recommendations. The syrup formulation is typically indicated for younger children.

Q: Can Ferrum Lek be used long-term for maintenance purposes?

Regulatory documents define treatment duration based on addressing specific deficiencies; for example, overt iron deficiency treatment lasts three to five months. A specific, indefinite long-term maintenance indication for non-pregnant adults is not explicitly stated in the patient information.

Q: Why are people sometimes advised to take iron supplements on an empty stomach for maximum absorption?

The general advice to take iron supplements on an empty stomach often applies to simple iron salts. However, official patient instructions for Ferrum Lek, due to its Iron Polymaltose Complex structure, specifically advise taking the medicine during or immediately after a meal.

Q: What are the recommendations for storing Ferrum Lek at home?

As required by regulatory standards, official patient leaflets include specific storage precautions for the product. These instructions detail the appropriate conditions needed to ensure the stability and integrity of the medicine while stored at home.

The official regulatory documents provide strict requirements for the storage and disposal of Ferrum Lek solution for injection to maintain its stability.

Official Storage Requirements

The medicine must be stored at a temperature not above 25 C and must not be frozen. Storage is required in the original package to ensure protection from light.

Like all medicines, the product must be kept out of the sight and reach of children.

Handling and Disposal

Before administration, the solution must be visually inspected; only a clear solution, free of visible particles, may be used. Any unused medicinal product or waste material must be disposed of in accordance with local requirements and should not be discarded via household waste or wastewater.